Concord Biotech Shows Strong Performance Amid Technical Evaluation Adjustments
Concord Biotech has recently experienced an evaluation adjustment, reflecting shifts in its technical indicators. The company reported strong Q4 FY24-25 results, achieving record net sales and operating profit margins. Institutional investor confidence is evident as their stake has increased, highlighting the company's solid long-term fundamentals and market performance.
Concord Biotech, a midcap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an evaluation adjustment, reflecting changes in its underlying technical trends. The stock's technical indicators have shifted, with the MACD showing a mildly bullish stance on a weekly basis, while the monthly perspective remains neutral. The Bollinger Bands also indicate a mildly bullish trend weekly, contrasting with a sideways movement on a monthly basis. In terms of performance, Concord Biotech reported a notable quarter in Q4 FY24-25, achieving its highest net sales at Rs 429.88 crore and a peak operating profit margin of 44.30%. The company has demonstrated strong long-term fundamentals, highlighted by an average Return on Equity (ROE) of 20.62% and a low Debt to Equity ratio. Additionally, institutional investors have increased their stake in the company, now holding 18.51%, which may reflect confidence in its financial health.
Despite recent fluctuations, the stock has delivered a return of 16.88% over the past year, outperforming broader market indices. This adjustment in evaluation underscores the dynamic nature of Concord Biotech's market position and performance indicators.
Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
